Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.

Article  PubMed  Google Scholar 

Safi H, Safi S, Hafezi-Moghadam A, Ahmadieh H. Early detection of diabetic retinopathy. Surv Ophthalmol. 2018;3:601–8.

Article  Google Scholar 

Sinclair SH, Schwartz S. Diabetic retinopathy: new concepts of screening, monitoring, and interventions. Surv Ophthalmol. 2024;69:882–92.

Article  PubMed  Google Scholar 

Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy. Surv Ophthalmol. 2002;47:S253–62.

Article  PubMed  Google Scholar 

Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154:2169–78.

Article  CAS  PubMed  Google Scholar 

Diabetes Control and Complications Trial (DCCT). Results of feasibility study. The DCCT research group. Diabetes Care. 1987;10:1–19.

Article  Google Scholar 

King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48:643–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu SK, Cheng KC, Mgbeahuruike MO, Lin YH, Wu CY, Wang HMD, et al. New insight into the effects of Metformin on diabetic retinopathy, aging and cancer: nonapoptotic cell death, immunosuppression, and effects beyond the Ampk pathway. IJMS. 2021;22:9453. https://doi.org/10.3390/ijms22179453.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wai KM, Mishra K, Koo E, Ludwig CA, Parikh R, Mruthyunjaya P, et al. Impact of glp-1 agonists and sglt-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study. Am J Ophthalmol. 2024;265:39–47.

Article  CAS  PubMed  Google Scholar 

Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2.CD009122.

Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–15.

Article  CAS  PubMed  Google Scholar 

Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23:B54–64.

PubMed  Google Scholar 

Klein R, Klein BE, Moss SE, Davis MD, De Mets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med. 1989;149(11):2427–32.

Article  CAS  PubMed  Google Scholar 

Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of Lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of Lisinopril in Insulin-Dependent diabetes mellitus. Lancet. 1998;351:28–31.

Article  CAS  PubMed  Google Scholar 

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, DIRECT Programme Study Group. Effect of Candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394–402.

Article  CAS  PubMed  Google Scholar 

Lin JC, Lai MS. Antihypertensive drugs and diabetic retinopathy in patients with type 2 diabetes. Ophthalmologica., Ophthalmologica. 2016;235:87–96.

Han G, Abariga SA, Sleilati G, Vedula SS, Hawkins BS. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2023;3:CD006127.

Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin epidemiologic study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261–5.

Article  CAS  PubMed  Google Scholar 

Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early treatment diabetic retinopathy study (ETDRS) report 22. Arch Ophthalmol. 1996;114:1079–84.

Article  CAS  PubMed  Google Scholar 

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G, Group DES. High concentrations of AGE-LDL and oxidized LDL in Circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012;35:1333–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d’Emden MC, Crimet DC, O’Connell RL. Effect of Fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet. 2007;370:1687–97.

Article  CAS  PubMed  Google Scholar 

Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M, Group AS. Rationale, design, and methods of the action to control cardiovascular risk in diabetes eye study (ACCORD-EYE) am. J Cardiol. 2007;99:i103–11.

Article  Google Scholar 

Qiao Q, Keinänen-Kiukaanniemi S, Läärä E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 1997;50:153–8.

Article  CAS  PubMed  Google Scholar 

Bahar A, Kashi Z, Ahmadzadeh Amiri A, Nabipour M. Association between diabetic retinopathy and hemoglobin level. Casp J Intern Med. 2013;4:759–62.

Google Scholar 

Giuffre G, Lodato G, Dardanoni G. Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: the Castedaccia eye study. Graefe’s Archives Clin Experimental Ophthalmol. 2004;242:535–40.

Article  Google Scholar 

Williams GA, Scott IU, Haller JA, Maguire AM, Marcus D, McDonald HR. Single-field fundus photography for diabetic retinopathy screening: a report by the American academy of ophthalmology. Ophthalmology. 2004;111:1055–62.

Article  PubMed  Google Scholar 

Drexler W, Fujimoto JG. State-of-the- art retinal optical coherence tomography. Prog Retin Eye Res. 2008;27: 45–88.

Vaughan N. Review of smartphone funduscopy for diabetic retinopathy screening. Survey of Ophthalmology. 2024;69:279–86.

Lord RK, Shah VA, San Filippo AN, Krishna R. Novel uses of smartphones in ophthalmology. Ophthalmology. 2010;117:1274.

Article  PubMed  Google Scholar 

Jamil AZ, Ali L, Tahir MY, Shiraz FS. Smart phone: a smart technology for fundus photography in diabetic retinopathy screening. Pak J Ophthalmol. 2018;34:225–30.

Google Scholar 

Kashyap N, Singh DK, Singh GK. Mobile Phone-Based Diabetic Retinopathy Detection System Using ANN-DWT. In: 2017 4th IEEE Uttar Pradesh Section International Conference on Electrical, Computer and Electronics (UPCON). 2017; 463–467.

Wintergerst MW, Petrak M, Li JQ, Larsen PP, Berger M, Holz FG, Krohne TU. Non-contact smartphone-based fundus imaging compared to conventional fundus imaging: a low-cost alternative for retinopathy of prematurity screening and Documentation. Sci Rep. 2019;9:1–8.

Article  Google Scholar 

Kim TN, Myers F, Reber C, Loury PJ, Loumou P, Webster D, et al. A smartphone-based tool for rapid, portable, and automated wide-field retinal imaging. Transl Vis Sci Technol. 2018;7:21.

Article  PubMed  PubMed Central  Google Scholar 

Remidio. Fundus on Phone (FOP); 2022.

Rajalakshmi R, Subashini R, Anjana RM, Mohan V. Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. Eye. 2018;32:1138.

Article  PubMed  PubMed Central  Google Scholar 

Flaxel CJ, Adelman RA, Bailey ST, et al. Diabet retinopathy Preferred Pract Pattern® Ophthalmol. 2020;127:66–P145.

Brown DM, Wykoff CC, Boyer D, et al. Evaluation of intravitreal Aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial. JAMA Ophthalmol. 2021;139:946–55.

Article  PubMed  Google Scholar 

Maturi RK, Glassman AR, Josic K et al. Four-year visual outcomes in the Protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy [published correction appears in JAMA. 2023;329:376–85.

Gross JG, Glassman AR, Liu D, et al. Five- year outcomes of panretinal photocoagulation vs intravitreous Ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136:1138–48.

Article  PubMed  PubMed Central  Google Scholar 

Sivaprasad S, Prevost AT, Vasconcelos JC, CLARITY Study Group, et al. Clinical efficacy of intravitreal Aflibercept versus panret i Nal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single- blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389:2193–203.

Article  CAS  PubMed  Google Scholar 

Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8. Ophthalmology. 1981;